Sizzle in the anti-cancer stem cell (CSC) space continued in the wake of the $177.25 million up-front deal between Oncomed Pharmaceuticals Inc. and Celgene Corp., which included $22.25 million as an equity investment and gives the latter options to as many as six candidates.